Represented Inari Medical, Inc. in connection with its $27 million Series C Preferred Stock financing, led by Gilde Healthcare and including existing investors Versant Ventures and U.S. Venture Partners. Read the press release.
Inari is a medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”). To date, the company has developed the FlowTriever and ClotTriever Systems, both of which are designed to enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.
The Newport Beach-based team representing Inari included Larry Cohn and Jeff Estes, with a diligence effort led by Arash Lessantiz.